May 7 (Reuters) - Crystal Genomics Inc:
* APTOSE BIOSCIENCES INC - EXERCISES EARLY OPTION FOR CG-806 LICENSE FROM CRYSTALGENOMICS
* APTOSE BIOSCIENCES INC - CO OWNS GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE CG-806 FOR ALL INDICATIONS OUTSIDE OF KOREA AND CHINA - LICENSED TERRITORY
* APTOSE BIOSCIENCES- CRYSTALGENOMICS ELIGIBLE FOR REGULATORY AND SALES MILESTONE PAYMENTS, AS WELL AS ROYALTIES ON PRODUCT SALES IN LICENSED TERRITORY
* APTOSE BIOSCIENCES INC - OPTION EXERCISE TRIGGERS A PAYMENT OF US $2.0 MILLION TO CRYSTALGENOMICS Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.